Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 5/20 | 0.35 |
| ▸ | THRB | P10828 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335376 | 0.89 | TP53 (0.47) | NR1I2KMT2AMEN1 | |
| SCHEMBL16168059 | 0.88 | NR1I2 (0.49) | NR1I2GAAHSD17B3HDAC8HDAC6 | |
| SCHEMBL13367231 | 0.88 | NR1I2 (0.49) | NR1I2GAAHSD17B3HDAC8HDAC6 | |
| SCHEMBL12337676 | 0.85 | NR1I2 (0.57) | NR1I2GAAHSD17B3HDAC8HDAC6 | |
| SCHEMBL12172229 | 0.85 | NR1I2 (0.47) | NR1I2GAAHSD17B3HDAC8HDAC6 | |
| SCHEMBL18800441 | 0.85 | NR1I2 (0.47) | NR1I2GAAHSD17B3HDAC8HDAC6 | |
| SCHEMBL25334516 | 0.85 | MGLL (0.46) | NR1I2 | |
| SCHEMBL25335071 | 0.82 | NR1I2 (0.47) | NR1I2 | |
| SCHEMBL28231242 | 0.82 | NR1I2 (0.47) | NR1I2L3MBTL1 | |
| SCHEMBL25334695 | 0.82 | NR1I2 (0.47) | NR1I2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001830-A1 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | SCRIPPS RESEARCH INST (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4472942-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | The Scripps Research Institute (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023147545-A9 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023147545-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001830-A1 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | PDCD1LG2, PDCD1, CD274 | NR1I2 3311/4885GAA 2547/4885HSD17B3 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.